Which diabetes drug helps lose belly fat better?
Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomized controlled study (PRIME‐V study)
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Two diabetes drugs were tested in Japanese patients already on another medicine. One drug (ipragliflozin) helped lose belly fat and improve blood sugar control in a different way than the other (metformin), which lowered blood sugar more but didn’t reduce belly fat as much.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 572 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Two diabetes drugs were tested in Japanese patients already on another medicine. One drug (ipragliflozin) helped lose belly fat and improve blood sugar control in a different way than the other (metformin), which lowered blood sugar more but didn’t reduce belly fat as much.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 572 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Publication
Authors
Koshizaka M, Ishikawa K, Ishibashi R, Maezawa Y, Sakamoto K, Uchida D, Nakamura S, Yamaga M, Yokoh H, Kobayashi A, Onishi S, Kobayashi K, Ogino J, Hashimoto N, Tokuyama H, Shimada F, Ohara E, Ishikawa T, Shoji M, Ide S, Ide K, Baba Y, Hattori A, Kitamoto T, Horikoshi T, Shimofusa R, Takahashi S, Nagashima K, Sato Y, Takemoto M, Newby LK, Yokote K, PRIME-V Study Group
Related Content
Claims (9)
Visceral fat is metabolically active tissue that disrupts insulin sensitivity and metabolic function, and tesamorelin reduces it through mechanisms that improve fat quality, muscle composition, and mitochondrial efficiency, leading to long-term metabolic resilience.
When Japanese adults with type 2 diabetes take sitagliptin plus ipragliflozin for 24 weeks, their outer fat layer shrinks, but those taking metformin gain outer fat, with a clear difference between the two treatments.
For Japanese adults with type 2 diabetes on sitagliptin, metformin lowers blood sugar more effectively than ipragliflozin after 24 weeks, with a clear difference in how much HbA1c drops.
For Japanese adults with type 2 diabetes on sitagliptin, metformin reduces bad cholesterol more than ipragliflozin, which actually raises bad cholesterol levels, with a clear difference between the two treatments.
For Japanese adults with type 2 diabetes taking sitagliptin, taking ipragliflozin for 24 weeks makes belly fat inside the body decrease more than taking metformin, with a noticeable difference in fat loss.